Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.

Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, Tognon G, Ragnoli M, Romani C, Tassi RA, Caimi L, Odicino FE, Sartori E, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2012 Dec;50(12):2189-98.

PMID:
23096757
2.

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A.

Br J Cancer. 2011 Apr 26;104(9):1418-25. doi: 10.1038/bjc.2011.109. Epub 2011 Apr 5.

3.

CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.

Presl J, Novotny Z, Topolcan O, Vlasak P, Kucera R, Fuchsova R, Vrzalova J, Betincova L, Svobodova S.

Anticancer Res. 2014 Jan;34(1):327-31.

PMID:
24403483
4.

HE4 is an independent prognostic marker in endometrial cancer patients.

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A.

Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.

PMID:
22525819
5.

HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).

Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, Fagö-Olsen CL, Andersen ES, Jochumsen K, Høgdall C.

Acta Obstet Gynecol Scand. 2013 Nov;92(11):1313-22. doi: 10.1111/aogs.12235.

PMID:
24032654
6.

Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.

Jiang T, Huang L, Zhang S.

BMC Cancer. 2015 May 12;15:396. doi: 10.1186/s12885-015-1260-7.

7.

Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.

Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU.

Am J Obstet Gynecol. 2013 Aug;209(2):142.e1-6. doi: 10.1016/j.ajog.2013.04.014. Epub 2013 Apr 10.

PMID:
23583212
8.

Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.

Minar L, Klabenesova I, Jandakova E, Zlamal F, Bienertova-Vasku J.

J Obstet Gynaecol Res. 2015 Oct;41(10):1644-52. doi: 10.1111/jog.12764. Epub 2015 Jul 30.

PMID:
26223178
9.

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.

Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kinalski M, Terlikowski SJ.

Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.

PMID:
26344910
10.

Serum HE4 as a prognostic marker in endometrial cancer--a population based study.

Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y, Freemantle M; ANECS Group, Webb PM, Spurdle AB, Obermair A.

Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.

PMID:
24211402
11.

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K.

Gynecol Oncol. 2008 Aug;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002. Epub 2008 May 21.

12.

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.

Gynecol Oncol. 2007 Feb;104(2):435-42. Epub 2006 Oct 4.

PMID:
17023034
13.

The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, Gurdol F.

Tumour Biol. 2013 Oct;34(5):2645-50. doi: 10.1007/s13277-013-0814-z. Epub 2013 May 3.

PMID:
23640061
14.
15.
16.

Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.

Knific T, Osredkar J, Smrkolj Š, Tonin I, Vouk K, Blejec A, Frković Grazio S, Rižner TL.

Gynecol Oncol. 2017 Oct;147(1):126-132. doi: 10.1016/j.ygyno.2017.07.130. Epub 2017 Jul 21.

PMID:
28735628
17.

The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.

Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A, Luvero D, Cafà EV, Dugo N, Angelucci M, Benedetti-Panici P.

Tumour Biol. 2013 Feb;34(1):571-6. doi: 10.1007/s13277-012-0583-0. Epub 2012 Nov 20.

PMID:
23179397
18.
19.

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A.

BMC Cancer. 2015 Feb 6;15:33. doi: 10.1186/s12885-015-1028-0.

20.

Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.

Wang Y, Han C, Teng F, Bai Z, Tian W, Xue F.

Int J Gynaecol Obstet. 2017 Jan;136(1):58-63. doi: 10.1002/ijgo.12010. Epub 2016 Nov 3.

PMID:
28099710

Supplemental Content

Support Center